CEbiotech.com - Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Most popular
searches

All articles

Filters:
Show search box
2015-08-05
Russia puts private science funders on „foreign agents” list.

Russia puts private science funders on „foreign agents” list.

A new law in Russia allows to create and execute a blacklist of so called “undesirable” organizations, whose principals can be sentenced to a fine or prison. Dmitry Zimin - Russia’s only private funder of scientific research – has announced a closure of his Dynasty Foundation after being labeled by t... Read more
Tags russia , Science Founding , Science policy , Dynasty Foundation
2014-12-26
Biocad company as a representative of Russian innovation

Biocad company as a representative of Russian innovation

Russian biotechnology sector as a part of central European region is still underfunded. However, despite political issues, it has a great potential for development with several leading companies shaping the regional market. Irina Gennadyevna, Public Relations Manager at BIOCAD, describes the company ... Read more
Tags russia , CPHI Worldwide , company , Biocad , Irina Gennadyevna
2013-02-20
Russia: Petrov’s Institute collaborates with Astra Zeneca

Russia: Petrov’s Institute collaborates with Astra Zeneca

Petrov Research Institute of Oncology is one of the oldest such places in Russia. Its broad experience in cancer research interested one of the biggest players on pharma market - Astra Zeneca.... Read more
Tags medicine , pharma , russia
2013-01-14
 Janssen Pharmaceutica cooperates with Russian NewVac – the symptom of Russian pharmaceutic

Janssen Pharmaceutica cooperates with Russian NewVac – the symptom of Russian pharmaceutical market evolution

On January 7th NewVac, the subsidiary of ChemRar High Tech Center (a Russian non-governmental R&D center for life sciences), announced a co-license agreement with Janssen Pharmaceutica, a pharmaceutical company of Johnson & Johnson. According to the contract NewVacs receives the exclusive rights for... Read more
Tags pharma , russia
2012-11-29
Russia corners the market of clinical trials

Russia corners the market of clinical trials

Lately, increased activity in clinical trials could be observed in the Russian market. Only in the second quarter of 2012 275 trials were approved, which is a 44% jump from the same period in 2011. According to Vladimir Putin words, Russia aims for being a super power in the sector of biomedicine and... Read more
Tags biotechnology , pharma , russia
2012-04-09
Clinical Trials in Central and Eastern Europe become the global advantage

Clinical Trials in Central and Eastern Europe become the global advantage

Newly developed drugs must be controlled in terms of efficiency and safety. At this step clinical trials are inevitable. They account for the biggest and also the longest part of total cost connected with introduction of new pharmaceuticals to the market. It is estimated that the global market of cli... Read more
Tags medicine , pharma , interview , russia